Abstract: This application provides a method for sending application context relocation ACR information and an apparatus. The method includes: An edge application server EAS receives first information from an edge enabler server EES, where the first information indicates whether ACR information is allowed to be sent by using an enabler layer. The EAS determines, based on at least the first information, a manner of sending the ACR information. The EAS sends the ACR information in the manner of sending the ACR information. According to the solution of this application, the manner of sending the ACR information by the EAS is associated with whether an EEC subscribes to the ACR information. Therefore, according to the method provided in this application, the EAS can send the ACR information in a correct manner, to ensure that the ACR information can be successfully sent to a terminal device.

Abstract: A method includes obtaining at least one of application context relocation (ACR) capability information supported by an edge application server (EAS), ACR capability information supported by an edge enabler client (EEC), ACR capability information supported by an application client (AC), or ACR capability information supported by an edge enabler server (EES). The method also includes selecting ACR mode information for the AC based on the at least one of the ACR capability information supported by the EAS, the ACR capability information supported by the EEC, the ACR capability information supported by the AC, or the ACR capability information supported by the EES. The ACR mode information indicates an identifier indicating the AC and an ACR scenario selected for the AC.

Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinoline (or similar) structure which function as antagonists of androgen receptor activity, and their use as therapeutics for the treatment of cancer (e.g., castration-resistant prostate cancer) and other conditions characterized with androgen receptor activity and/or androgen receptor expression.

Abstract: An aminoacylation/translation (AIT) system based on the protein synthesis system from the pathogen Pseudomonas aeruginosa, was used to screen chemical compounds for identifying inhibitors of protein synthesis. This system includes elongation factors: EF-Tu, EF-Ts and EF-G, aminoacyl tRNA synthetase (aaRS) specific for phenylalanine, PheRS, and ribosomes isolated from cultures of Pseudomonas aeruginosa. Compounds identified using this assay have been shown to contain broad spectrum activity against both Gram+ and Gram? pathogens. Methods of using the identified compounds, as well as derivatives and analogues of these compounds, as antimicrobial agents against bacterial infections are described.

Abstract: An aminoacylation/translation (AIT) system based on the protein synthesis system from the pathogen Pseudomonas aeruginosa, was used to screen chemical compounds for identifying inhibitors of protein synthesis. This system includes elongation factors: EF-Tu, EF-Ts and EF-G, aminoacyl tRNA synthetase (aaRS) specific for phenylalanine, PheRS, and ribosomes isolated from cultures of Pseudomonas aeruginosa. Compounds identified using this assay have been shown to contain broad spectrum activity against both Gram+ and Gram? pathogens. Methods of using the identified compounds, as well as derivatives and analogues of these compounds, as antimicrobial agents against bacterial infections are described.